Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2016

01.01.2016 | Preclinical study

Clinical utility of reverse phase protein array for molecular classification of breast cancer

verfasst von: Ola H. Negm, Abir A. Muftah, Mohammed A. Aleskandarany, Mohamed R. Hamed, Dena A. J. Ahmad, Christopher C. Nolan, Maria Diez-Rodriguez, Patrick J. Tighe, Ian O. Ellis, Emad A. Rakha, Andrew R. Green

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formalin-fixed paraffin-embedded (FFPE) breast cancer tissues into molecular classes used in the Nottingham prognostic index plus (NPI+) determined by immunohistochemistry (IHC). Proteins were extracted from FFPE breast cancer tissues using three extraction protocols: the Q-proteome FFPE Tissue Kit (Qiagen, Hilden, Germany) and two in-house methods using Laemmli buffer with either incubation for 20 min or 2 h at 105 °C. Two preparation methods, full-face sections and macrodissection, were used to assess the yield and quality of protein extracts. Ten biomarkers used for the NPI+ (ER, PgR, HER2, Cytokeratins 5/6 and 7/8, EGFR, HER3, HER4, p53 and Mucin 1) were quantified using RPPA and compared to results determined by IHC. The Q-proteome FFPE Tissue Kit produced significantly higher protein concentration and signal intensities. The intra- and inter-array reproducibility assessment indicated that RPPA using FFPE lysates was a highly reproducible and robust technique. Expression of the biomarkers individually and in combination using RPPA was highly consistent with IHC results. Macrodissection of the invasive tumour component gave more reliable results with the majority of biomarkers determined by IHC, (80 % concordance) compared with full-face sections (60 % concordance). Our results provide evidence for the technical feasibility of RPPA for high-throughput protein expression profiling of FFPE breast cancer tissues. The sensitivity of the technique is related to the quality of extracted protein and purity of tumour tissue. RPPA could provide a quantitative technique alternative to IHC for the biomarkers used in the NPI+.
Literatur
1.
Zurück zum Zitat Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM et al (2008) Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 132(12):1929–1935PubMed Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM et al (2008) Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 132(12):1929–1935PubMed
2.
Zurück zum Zitat Hood BL, Conrads TP, Veenstra TD (2006) Unravelling the proteome of formalin-fixed paraffin-embedded tissue. Brief Funct Genomic Proteomic 5(2):169–175PubMedCrossRef Hood BL, Conrads TP, Veenstra TD (2006) Unravelling the proteome of formalin-fixed paraffin-embedded tissue. Brief Funct Genomic Proteomic 5(2):169–175PubMedCrossRef
3.
Zurück zum Zitat Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, White S, Memeo L, Colarossi C, Petricoin EF 3rd et al (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 6(8):e23780PubMedPubMedCentralCrossRef Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, White S, Memeo L, Colarossi C, Petricoin EF 3rd et al (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 6(8):e23780PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd (2007) Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics 4(3):157–164PubMed Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd (2007) Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics 4(3):157–164PubMed
5.
Zurück zum Zitat Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL et al (2002) Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160(2):449–457PubMedPubMedCentralCrossRef Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL et al (2002) Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160(2):449–457PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Becker KF, Schott C, Becker I, Hofler H (2008) Guided protein extraction from formalin-fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains. Proteomics Clin Appl 2(5):737–743PubMedCrossRef Becker KF, Schott C, Becker I, Hofler H (2008) Guided protein extraction from formalin-fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains. Proteomics Clin Appl 2(5):737–743PubMedCrossRef
7.
Zurück zum Zitat Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53(2):125–130PubMedPubMedCentralCrossRef Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53(2):125–130PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed
9.
Zurück zum Zitat Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR et al (2013) Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer 109(7):1886–1894PubMedPubMedCentralCrossRef Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR et al (2013) Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer 109(7):1886–1894PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO (2014) Nottingham prognostic index plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer 110(7):1688–1697PubMedPubMedCentralCrossRef Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO (2014) Nottingham prognostic index plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer 110(7):1688–1697PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Spurrier B, Ramalingam S, Nishizuka S (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3(11):1796–1808PubMedCrossRef Spurrier B, Ramalingam S, Nishizuka S (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3(11):1796–1808PubMedCrossRef
12.
Zurück zum Zitat Brase JC, Mannsperger H, Frohlich H, Gade S, Schmidt C, Wiemann S, Beissbarth T, Schlomm T, Sultmann H, Korf U (2010) Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 8:36PubMedPubMedCentralCrossRef Brase JC, Mannsperger H, Frohlich H, Gade S, Schmidt C, Wiemann S, Beissbarth T, Schlomm T, Sultmann H, Korf U (2010) Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Sci 8:36PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704–6714PubMedPubMedCentralCrossRef Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704–6714PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, Kublbeck M, Henjes F, Ward A, Tschulena U, Zweig K et al (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8:570PubMedPubMedCentralCrossRef Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, Kublbeck M, Henjes F, Ward A, Tschulena U, Zweig K et al (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8:570PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T et al (2012) Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 1:e16PubMedPubMedCentralCrossRef Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T et al (2012) Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 1:e16PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E (2014) Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res 13(6):2846–2855PubMedCrossRef Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E (2014) Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res 13(6):2846–2855PubMedCrossRef
17.
Zurück zum Zitat Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E et al (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178(2):548–571PubMedPubMedCentralCrossRef Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E et al (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178(2):548–571PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Arbogast S et al (2013) Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteomics 12(9):2615–2622PubMedPubMedCentralCrossRef Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Arbogast S et al (2013) Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteomics 12(9):2615–2622PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U (2007) Infrared-based protein detection arrays for quantitative proteomics. Proteomics 7(4):558–564PubMedCrossRef Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U (2007) Infrared-based protein detection arrays for quantitative proteomics. Proteomics 7(4):558–564PubMedCrossRef
20.
Zurück zum Zitat Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA (2014) Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat 145(2):339–348PubMedCrossRef Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA (2014) Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat 145(2):339–348PubMedCrossRef
21.
Zurück zum Zitat Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, Fairclough LC, Tighe PJ (2014) A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur J Immunol 44(7):2096–2110PubMedPubMedCentralCrossRef Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, Fairclough LC, Tighe PJ (2014) A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur J Immunol 44(7):2096–2110PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U (2010) RPPanalyzer: analysis of reverse-phase protein array data. Bioinformatics 26(17):2202–2203PubMedCrossRef Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U (2010) RPPanalyzer: analysis of reverse-phase protein array data. Bioinformatics 26(17):2202–2203PubMedCrossRef
23.
Zurück zum Zitat McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMed McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMed
24.
Zurück zum Zitat Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H (2007) Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211(3):370–378PubMedCrossRef Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H (2007) Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211(3):370–378PubMedCrossRef
25.
Zurück zum Zitat Casadonte R, Caprioli RM (2011) Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc 6(11):1695–1709PubMedPubMedCentralCrossRef Casadonte R, Caprioli RM (2011) Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc 6(11):1695–1709PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Nirmalan NJ, Hughes C, Peng J, McKenna T, Langridge J, Cairns DA, Harnden P, Selby PJ, Banks RE (2011) Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res 10(2):896–906PubMedPubMedCentralCrossRef Nirmalan NJ, Hughes C, Peng J, McKenna T, Langridge J, Cairns DA, Harnden P, Selby PJ, Banks RE (2011) Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res 10(2):896–906PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, Uzzau S (2009) Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics 9(15):3815–3823PubMedCrossRef Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, Uzzau S (2009) Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics 9(15):3815–3823PubMedCrossRef
28.
Zurück zum Zitat Wolff C, Schott C, Malinowsky K, Berg D, Becker KF (2011) Producing reverse phase protein microarrays from formalin-fixed tissues. Methods Mol Biol 785:123–140PubMedCrossRef Wolff C, Schott C, Malinowsky K, Berg D, Becker KF (2011) Producing reverse phase protein microarrays from formalin-fixed tissues. Methods Mol Biol 785:123–140PubMedCrossRef
29.
Zurück zum Zitat Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52(1–3):79–98PubMedCrossRef Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52(1–3):79–98PubMedCrossRef
30.
Zurück zum Zitat Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F et al (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6(4):129–151PubMedPubMedCentralCrossRef Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F et al (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6(4):129–151PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL (2010) Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 19(4):982–991PubMedPubMedCentralCrossRef Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL (2010) Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 19(4):982–991PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7(4):1508–1517PubMedCrossRef Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7(4):1508–1517PubMedCrossRef
Metadaten
Titel
Clinical utility of reverse phase protein array for molecular classification of breast cancer
verfasst von
Ola H. Negm
Abir A. Muftah
Mohammed A. Aleskandarany
Mohamed R. Hamed
Dena A. J. Ahmad
Christopher C. Nolan
Maria Diez-Rodriguez
Patrick J. Tighe
Ian O. Ellis
Emad A. Rakha
Andrew R. Green
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3654-2

Weitere Artikel der Ausgabe 1/2016

Breast Cancer Research and Treatment 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.